GKOS
Glaukos Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -11.8% ·
share flow +8.9% ·
net new positions -13.3%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 125 | +9 | 42.84M | $5.95B | +15 | −5 |
| Q1 2026 | 118 | -1 | 46.55M | $5.02B | +6 | −8 |
| Q4 2025 | 118 | 0 | 48.22M | $5.44B | +2 | −1 |
| Q3 2025 | 22 | +5 | 29.69M | $2.42B | +5 | −1 |
| Q2 2025 | 15 | -2 | 32.65M | $3.37B | +1 | −3 |
| Q1 2025 | 14 | -2 | 8.81M | $867.57M | +1 | −3 |
| Q4 2024 | 16 | -1 | 9.74M | $1.46B | — | −1 |
| Q3 2024 | 16 | 0 | 7.06M | $919.99M | +1 | −1 |
| Q2 2024 | 16 | — | 6.75M | $798.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.72M | — | $901.15M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 2 | Fidelity (FMR) ✦ | 6.34M | — | $654.51M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | The Vanguard Group ✦ (passive) | 6.11M | — | $631.33M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Wellington Management ✦ | 3.24M | +41.6% | $335.11M | 0.1% | ▲ Add | 5 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (passive) | 2.09M | +5.3% | $215.91M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | PRIMECAP Management ✦ | 1.83M | +50.0% | $188.81M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 1.33M | +9.5% | $137.45M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Capital World Investors ✦ | 850.89K | +54.6% | $87.89M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 738.83K | +12.8% | $76.31M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 719.26K | New | $74.29M | 0.2% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 320.51K | -23.8% | $33.11M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Marshall Wace ✦ | 230.69K | -33.1% | $23.83M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 13 | T. Rowe Price ✦ | 107.54K | +184.8% | $11.11M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | GAMCO Investors ✦ | 8.00K | +10.7% | $826,423 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 6.34K | -18.6% | $654,962 | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $74.29M | 0.2% |
Exited
| Millennium Management | $7.70M | was 0.0% |
| Bridgewater Associates | $231,878 | was 0.0% |
| D. E. Shaw & Co. | $206,780 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 57.55M shares, $6.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 888 sh · $145,570
Officer · 312 sh · $51,667
Officer · 327 sh · $53,883
Officer · 167 sh · $25,334
Officer · 1.08K sh · $167,735
Officer · 229 sh · $35,321
Officer · 136 sh · $20,769
Officer · 103 sh · $16,810
Officer · 345 sh · $56,787
Officer · 191 sh · $31,744
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology